FY2025 EPS Estimates for Pharming Group Increased by Analyst

Pharming Group N.V. Sponsored ADR (NASDAQ:PHAR) – Investment analysts at HC Wainwright increased their FY2025 earnings estimates for shares of Pharming Group in a note issued to investors on Wednesday, February 4th. HC Wainwright analyst J. Pantginis now forecasts that the company will post earnings per share of $0.10 for the year, up from their previous estimate of $0.02. The consensus estimate for Pharming Group’s current full-year earnings is ($0.20) per share. HC Wainwright also issued estimates for Pharming Group’s FY2026 earnings at $0.49 EPS and FY2027 earnings at $0.66 EPS.

Other equities analysts also recently issued reports about the company. Zacks Research downgraded Pharming Group from a “strong-buy” rating to a “hold” rating in a research note on Thursday, January 1st. Weiss Ratings reaffirmed a “hold (c-)” rating on shares of Pharming Group in a research note on Monday, December 22nd. Finally, Wall Street Zen upgraded Pharming Group to a “strong-buy” rating in a report on Saturday, December 27th. Two analysts have rated the stock with a Buy rating and two have issued a Hold rating to the stock. According to MarketBeat, Pharming Group presently has a consensus rating of “Moderate Buy” and a consensus target price of $38.00.

Pharming Group Stock Performance

Shares of PHAR opened at $16.09 on Monday. The company has a 50-day simple moving average of $17.75 and a 200-day simple moving average of $15.36. Pharming Group has a 52-week low of $7.50 and a 52-week high of $21.34. The company has a quick ratio of 2.39, a current ratio of 3.16 and a debt-to-equity ratio of 0.35. The company has a market capitalization of $1.13 billion, a PE ratio of -1,607.39 and a beta of -0.01.

Pharming Group (NASDAQ:PHAR) last issued its quarterly earnings results on Thursday, November 6th. The company reported $0.10 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.05 by $0.05. Pharming Group had a net margin of 0.30% and a return on equity of 0.46%. The business had revenue of $97.30 million for the quarter, compared to analyst estimates of $98.22 million.

Hedge Funds Weigh In On Pharming Group

An institutional investor recently bought a new position in Pharming Group stock. EverSource Wealth Advisors LLC purchased a new position in Pharming Group N.V. Sponsored ADR (NASDAQ:PHAR) in the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund purchased 2,979 shares of the company’s stock, valued at approximately $32,000. 0.03% of the stock is owned by institutional investors and hedge funds.

About Pharming Group

Pharming Group N.V. is a clinical-stage biopharmaceutical company headquartered in Leiden, the Netherlands, with a primary focus on developing and commercializing innovative protein replacement therapies for patients living with rare diseases. The company employs a proprietary transgenic technology platform designed to produce recombinant human proteins in the milk of transgenic animals, enabling scalable and cost-efficient manufacturing of complex therapeutic proteins.

The company’s lead product, RUCONEST (recombinant human C1 esterase inhibitor), is approved for the treatment of acute hereditary angioedema (HAE) attacks in multiple markets, including the United States and Europe.